Effect of hirulog-like peptide on balloon catheter injury-induced neointimal formation in femoral arteries of minipigs and relationship with inflammatory mediators

J Vasc Res. 2010;47(3):262-9. doi: 10.1159/000257340. Epub 2009 Nov 11.

Abstract

Vascular intervention-induced neointimal formation is a major drawback for managing atherosclerotic cardiovascular diseases using invasive vascular procedures. Our previous studies demonstrated that hirulog-like peptide (HLP) reduced balloon catheter dilation-induced neointimal formation or restenosis in carotid arteries of rats or atherosclerotic rabbits with less interruption in coagulation or bleeding than heparin or hirulog-1. The present study examined the effect of HLP on balloon catheter injury-induced neointimal formation in femoral arteries of minipigs. Intravenous infusion of HLP (1.6 mg/kg/h for 4 h started 0.5 h before the intervention) or unfractured heparin (50 U/kg/h for 4 h) significantly reduced neointimal formation in femoral arteries 4 weeks after intervention compared with the vehicle. Heparin, but not HLP, significantly prolonged activated partial thromboplastin time. HLP or heparin significantly reduced vascular intervention-induced increases in C-reactive protein, P-selectin and interleukin-6 in serum. HLP, but not heparin, normalized vascular injury-induced increase in P-selectin in platelets. The results of the present study suggest that HLP is an effective agent for preventing balloon catheter injury-induced neointimal formation in femoral arteries of minipigs. The beneficial effects of HLP on vascular injury-induced neointimal formation may partially result from its inhibition on inflammatory mediators.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology*
  • Blood Coagulation / drug effects
  • C-Reactive Protein / metabolism
  • Catheterization / adverse effects*
  • Femoral Artery / drug effects*
  • Femoral Artery / immunology
  • Femoral Artery / injuries
  • Femoral Artery / pathology
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / pharmacology*
  • Heparin / pharmacology
  • Hirudins / administration & dosage
  • Hirudins / pharmacology*
  • Inflammation Mediators / blood*
  • Infusion Pumps
  • Infusions, Intravenous
  • Interleukin-6 / blood
  • Male
  • Models, Animal
  • P-Selectin / blood
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / pharmacology*
  • Platelet Aggregation / drug effects
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology
  • Swine
  • Swine, Miniature
  • Time Factors
  • Tunica Intima / drug effects*
  • Tunica Intima / immunology
  • Tunica Intima / injuries
  • Tunica Intima / pathology

Substances

  • Anti-Inflammatory Agents
  • Fibrinolytic Agents
  • Hirudins
  • Inflammation Mediators
  • Interleukin-6
  • P-Selectin
  • Peptide Fragments
  • Recombinant Proteins
  • Heparin
  • C-Reactive Protein
  • bivalirudin